
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
Key Takeaways
- FDA approved cemdisiran as the first siRNA for gMG and the only FDA-approved subcutaneous gMG option administered four times annually, restricted to anti-AChR–positive adults.
- Mechanistically, cemdisiran degrades C5 mRNA, reduces circulating C5, and attenuates terminal complement–mediated NMJ injury central to AChR-positive disease biology.
The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.
Cemdisiran (Livsayis; Regeneron), a subcutaneous small interfering RNA (siRNA) therapy dosed every 3 months, has received FDA approval for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), Regeneron
Cemdisiran targets complement component 5 (C5). It degrades the messenger RNA that encodes C5, lowering circulating C5 and limiting terminal complement activation, a key driver of AChR-positive gMG. In this form of the disease, abnormal antibodies activate complement and disrupt signaling between nerves and muscles, causing weakness that can affect facial expression, speech, swallowing, mobility, and breathing. Regeneron estimates that about 85,000 people in the US have gMG.
What Did the NIMBLE Trial Show?
Approval was based on the phase 3 NIMBLE (
At week 24, patients receiving cemdisiran improved by 4.5 points on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the primary end point, compared with 2.2 points with placebo, a placebo-adjusted difference of 2.3 points (P = .0005).1,2 Responders, defined as those with at least a 3-point improvement, made up 76.6% of the cemdisiran group versus 44.1% with placebo (P < .001).1
On the Quantitative Myasthenia Gravis (QMG) scale, a key secondary end point, scores improved by 4.2 points with cemdisiran versus 1.5 points with placebo, a placebo-adjusted difference of 2.8 points (P = .0015).1,3 Patients with at least a 5-point improvement accounted for 48.4% versus 19.0% (P < .001).1
Regeneron reported MG-ADL improvements as early as 2 weeks that deepened over time and were sustained through 24 weeks with no sign of waning. Full results, published in The Lancet and presented at the 2026 American Academy of Neurology Annual Meeting, showed the combination arm also improved significantly vs placebo (4.0 vs 2.2 points; P = .0086) but offered no numerical advantage over cemdisiran alone (4.5 points).2,4 Tuan Vu, MD, a professor of neurology at the University of South Florida Morsani College of Medicine and global principal investigator of NIMBLE, said the results showed rapid, deep disease control maintained through the end of dosing intervals.1
What Safety Requirements Apply?
Cemdisiran carries a boxed warning for serious meningococcal infections caused by Neisseria meningitidis, which can become life-threatening quickly.1,3 Meningococcal vaccination should be completed at least 2 weeks before the first dose unless delaying therapy poses a greater risk. If treatment must begin urgently in a patient who is not up to date on vaccines, antibacterial prophylaxis is required, and vaccines should be given as soon as possible. Patients must carry a patient safety card during treatment and for 12 months after the last dose.1
The therapy also increases susceptibility to infections from encapsulated bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae.3 Common adverse reactions, occurring in at least 5% of patients and more often than with placebo, were injection site reactions, viral infections, and urinary tract infections.1,3 In the pivotal study and its extension, serious infections were reported in 5% of patients treated with cemdisiran, including one fatal case of pneumonia during the extension period.3 Data on use in pregnancy are limited; there are no data on breastfeeding, and safety and effectiveness in children have not been established.
Cemdisiran is available only through the Livsayis Risk Evaluation and Mitigation Strategy, which requires provider enrollment and patient counseling and education.1,3
When Will Cemdisiran Be Available?
Regeneron did not include a US launch date or pricing in its announcement.1 Each dose must be administered by a health care provider.3 Regeneron's myRARE program offers insurance benefit verification and information on potential financial support.1 A regulatory submission is under review in the European Union, with a decision expected in the second half of 2027.
George D. Yancopoulos, MD, PhD, board cochair, president, and chief scientific officer of Regeneron, called the therapy an important new option for people living with gMG who need effective disease control without a heavy treatment burden.1
References
1. Livsayis (cemdisiran) approved by FDA as first and only siRNA therapy for generalized myasthenia gravis. News release. Regeneron Pharmaceuticals. November 18, 2026. Accessed November 19, 2026.
2. Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2
3. Livsayis. Prescribing information. Regeneron Pharmaceuticals, Inc.; 2026. Accessed November 19, 2026.
4. Bonavitacola J, Vu T. NIMBLE trial shows efficacy of cemdisiran in gMG: Tuan Vu, MD. AJMC. April 21, 2026. Accessed November 19, 2026.
Related to this article








